SNGXSOLIGENIX, INC.

Nasdaq www.soligenix.com


$ 4.12 $ 0.26 (6.82 %)    

Wednesday, 04-Sep-2024 14:56:18 EDT
QQQ $ 460.65 $ -1.20 (-0.26 %)
DIA $ 410.44 $ 0.17 (0.04 %)
SPY $ 550.83 $ -1.13 (-0.2 %)
TLT $ 98.96 $ 1.26 (1.29 %)
GLD $ 230.43 $ 0.14 (0.06 %)
$ 4.07
$ 3.77
$ 4.05 x 136
-- x --
$ 3.76 - $ 4.20
$ 1.83 - $ 32.00
165,254
na
9.28M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-15-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-21-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-18-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-26-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-06-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-11-2017 03-31-2017 10-Q
31 03-27-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-24-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-25-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 soligenix-q2-2024-gaap-eps-131-beats-177-estimate

Soligenix (NASDAQ:SNGX) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.77) by ...

 soligenix-plans-to-initiate-patient-enrollment-in-the-confirmatory-flash-2-study-with-hybryte-by-the-end-of-2024-continues-to-explore-the-potential-of-hybryte-in-treating-other-dermatological-conditions-such-as-psoriasis

PCG Digital -- Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company, is making significant strides in the trea...

 nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why

Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study.

 soligenix-shares-resume-trade
Soligenix Shares Resume Trade
07/09/2024 13:57:06

Core News & Articles
Market-Moving News for July 9th
07/09/2024 12:29:07

SNGX: 142% | Soligenix shares are trading higher after the company announced interim results for extended HyBryte treatment in ...

 soligenix-announces-hybryte-treatment-results-in-early-stage-cutaneous-t-cell-lymphoma

"In the Phase 3 FLASH study, HyBryte™ was shown to be efficacious with a promising safety profile. With limited treatment o...

 soligenix-announces-interim-results-for-extended-hybryte-treatment-in-early-stage-ctcl-patients

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and comm...

 watching-soligenix-zacks-small-cap-research-gives-stock-32-price-valuation-says-model-is-highly-dependent-upon-continued-clinical-success-of-the-companys-pipeline-and-will-be-adjusted-accordingly-based-upon-future-clinical-results

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_06142024_SNGX_Bautz.pdf

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION